The funding was meant to help the U.S. prepare for pandemics triggered by avian flu strains, but now leaves the future of ...

After a three-year drought, the industry is questioning whether the window for medtech public offerings is open following a ...

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Weeks after shelving a TIGIT drug prospect, the biotech is seeking to sell off its assets and intellectual property in a bid ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Commissioner Martin Makary and two of his deputies aim to meet with drugmaker CEOs to discuss how the agency can “modernize” ...

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...

To meet these demands, biopharma leaders are rethinking their digital infrastructure. Integrated informatics platforms—once ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.